Publikationen in Zusammenarbeit mit Forschern von Universidad de Cantabria (7)

2022

  1. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

    Biomolecules, Vol. 12, Núm. 11

2021

  1. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

    Biomedicine and Pharmacotherapy, Vol. 144

2018

  1. Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia [Oncotarget, 8 (2017) (29679-29698)] Doi: 10.18632/oncotarget.11425

    Oncotarget

2017

  1. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

    Oncotarget, Vol. 8, Núm. 18, pp. 29679-29698

  2. ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA

    Oncogene, Vol. 36, Núm. 12, pp. 1733-1744

2013

  1. Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue

    Stem Cells, Vol. 31, Núm. 6, pp. 1075-1085

2002

  1. Mitogen-activated protein kinase routes as targets in the action of Diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells

    Molecular Cancer Therapeutics, Vol. 1, Núm. 10, pp. 811-819